[1] Andreoli SP. Acute renal failure [J]. Curr Opin Pediatr, 2002, 14(2):183-188.
[2] Flynn JT. Choice of dialysis modality for management of pediatric acute renal failure [J]. Pediatr Nephrol, 2002,17(1):61-69.
[3] Williams DM, Sreedhar SS, Mickell JJ, et al. Acute kidney failure: a pediatric experience over 20 years [J]. Arch Pediatr Adolesc Med, 2002,156(9):893-900.
[4] Vachvanichsanong P, Dissaneewate P, Lim A, et al. Childhood acute renal failure: 22-year experience in a university hospital in southern Thailand [J]. Pediatrics, 2006, 118(3): e786-e791.
[5] Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a teritary care center from 1999 to 2001 [J]. Am J Kidney Dis, 2005, 45(1): 96-101.
[6] Cao Y, Yi ZW, Zhang H, et al. Etiology and outcomes of acute kidney injury in Chinese children: a prospective multicentre investigation [J]. BMC Urol, 2013, 13(1):41-48.
[7] Langenberg C, Wan L, Egi M, et al. Renal blood flow in experimental septic acute renal failure [J]. Kidney Int, 2006, 69(11):1996-2002.
[8] Chen S, Apostolova MD, Cherian MG, et al. Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells [J]. Lab Invest, 2000, 80(8): 1311-1321.
[9] Chvojka J, Sykora R, Karvunidis T, et al. New developments in septic acute kidney injury [J]. Physiol Res, 2010, 59(6): 859-869.
[10] Himmelfarb J, McMonagle E, Freedman S, et al. Oxidative stress is increased in critically ill patients with acute renal failure [J]. J Am Soc Nephrol, 2004, 15(9): 2449-2456.
[11] Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury [J]. Pediatr Nephrol, 2008, 23(12):2151-2157.
[12] Devarajan P. Emerging biomarkers of acute kidney injury [J]. Contrib Nephrol, 2007, 156: 203-212.
[13] Devarajan P. Proteomics for biomarker discovery in acute kidney injury [J]. Semin Nephrol, 2007, 27(6): 637-651.
[14] Devarajan P. Proteomics for the investigation of acute kidney injury [J]. Contrib Nephrol, 2008,160:1-16.
[15] Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock [J]. Crit Care Med, 2004, 32(3):858-873.
[16] Russell JA. Management of sepsis [J]. N Engl J Med, 2006, 355(16):1699-1713.
[17] Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock [J]. Anesthesiology, 2002, 96(3): 576-582.
[18] Burton CJ, Tomson CR. Can the use of low-dose dopamine for treatment of acute renal failure be justified? [J]. Postgrad Med J, 1999, 75(88):269-274.
[19] Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial [J]. Clin Nephrol, 1981,15(2):90-96.
[20] Kleinknecht D, Ganeval D, Gonzalez-Duque LA, et al. Furosemide in acute oliguric renal failure. A controlled trial [J]. Nephron, 1976,17(1):51-58.
[21] Shilliday IR, Quinn KJ, Allison ME. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study [J]. Nephrol Dial Transplant, 1997,12(12):2592-2596. |
